NeuraWorx Closes Oversubscribed Seed Round Led by Nexus NeuroTech to Advance Neurotechnology Therapy for CNS Disorders

Audio By Carbonatix

EXCELSIOR, Minn.--(BUSINESS WIRE)--Dec 18, 2025--

Neuraworx Medical Technology, Inc., a neurotechnology company developing first-in-class bioelectronic solutions for brain health originally developed at the University of Wisconsin-Madison, today announced the successful close of its oversubscribed Seed funding round led by Nexus NeuroTech Ventures, with participation from Foothill Ventures, Verge HealthTech Fund, Wisconsin Alumni Research Foundation (WARF), and other leading neurotech investors.

“NeuraWorx is addressing a foundational and underexplored mechanism in brain health: cerebrovascular and glymphatic dysfunction, which is increasingly implicated in neurodegenerative and neuropsychiatric diseases,” said John Propst, PhD, MBA, Principal at Nexus NeuroTech Ventures. “What differentiated this opportunity for Nexus was the strength of the underlying physiology, the clarity of the mechanistic hypothesis, and a robust chain of preclinical and emerging clinical evidence supporting translatability. The company's development strategy is anchored in objective biomarkers and clinically meaningful endpoints, and we are excited to support the team as they advance a rigorous clinical and regulatory program to translate this platform into durable benefit for patients.”

“This funding validates our science and accelerates our mission to transform brain health for everyone,” said Chris Minar, CEO and Co-Founder of NeuraWorx. “We are grateful for Nexus NeuroTech's strategic partnership and the confidence of our entire investor syndicate. With this capital, we are immediately scaling our team to attract world-class talent in neuroscience, clinical development, and regulatory affairs—people who share our vision of bringing the first-in-class Cerebrovascular Pacing System™ to patients as quickly and safely as possible.”

For company updates and information, follow NeuraWorx on LinkedIn or visit www.neuraworx.com.

About Neuraworx Medical Technology, Inc.


NeuraWorx is a clinical-stage neurotechnology company pioneering bioelectronic solutions to restore cerebrovascular and glymphatic function. Based in Excelsior, MN, the company is developing the Cerebrovascular Pacing System™, a proprietary platform designed to enhance brain fluid dynamics for the treatment of central nervous system disorders. For more information, visit www.neuraworx.com.

About Nexus NeuroTech Ventures


Nexus NeuroTech Ventures is an investment firm dedicated to advancing pioneering technologies — including medical devices, software, diagnostics, technology-enabled care services and research tools — for brain disorders. Spanning seed through crossover, Nexus invests with the goal of improving the lives of people affected by neurodevelopmental, neurodegenerative and neuropsychiatric conditions. See nexusneurotech.com for more information.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251217796461/en/

CONTACT: Media Contact:


Chris Minar


Neuraworx Medical Technology, Inc.


[email protected]


(612) 562-9354

KEYWORD: MINNESOTA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES NEUROLOGY CLINICAL TRIALS RESEARCH SCIENCE BIOTECHNOLOGY

SOURCE: Neuraworx Medical Technology, Inc.

Copyright Business Wire 2025.

PUB: 12/18/2025 12:26 PM/DISC: 12/18/2025 12:26 PM

http://www.businesswire.com/news/home/20251217796461/en